Jefferies analyst Brian Tanquilut reiterated a "Buy" rating on CVS Health with a $120 price target, implying a 28% upside from Monday's closing price. The analyst named CVS as one of his top picks, noting that the company's management expects earnings per share (EPS) of at least $8.44 in 2027 and anticipates resuming share buybacks in late 2026 or early 2027. Additionally, the ongoing recovery of CVS's Aetna unit is performing well, with operating profit up over $2 billion year-to-date in 2026.